Compounding drugs; exceptions for distribution within hospital or health system.
Summary
HB1905 amends Virginia’s law governing pharmacy compounding to clarify when pharmacists may prepare compounded drug products and how those products may be labeled, recorded, and distributed. The bill preserves the general rule that compounding must be tied to valid prescriptions or a documented pattern of anticipated prescriptions, and it continues to require compliance with USP-NF standards, pharmacist supervision, quality assurance, and detailed recordkeeping.
A central change is a new or clarified exception allowing compounded drugs to be distributed within a health system under common ownership when the products are administered only to patients within the hospital or health system. The bill also continues to permit limited distribution to veterinarians, including for companion animals in emergency situations, and allows delivery to alternate delivery locations and office-based administration by certain practitioners under specified conditions. It reinforces labeling requirements for compounded products, including special labeling for products intended for administration in a prescriber’s practice location and for veterinary use.
Impact
The bill amends and reenacts Virginia Code § 54.1-3410.2, affecting the statutory framework for pharmacy compounding, sterile compounding notification, and limits on redistribution of compounded drugs. It narrows the general prohibition on subsequent distribution by creating an express exception for distribution within hospitals or health systems under common ownership, while keeping restrictions on commercial resale and distribution to other pharmacies or entities. It also maintains and clarifies requirements for labeling, beyond-use dating, record retention, bulk drug substance sourcing, and board oversight of sterile compounding pharmacies.
Sentiment
The bill appears to have broad bipartisan support and little visible opposition. It advanced unanimously through subcommittee, full committee, and both chambers, with recorded votes of 8-0, 22-0, 97-0, 14-0, 38-0, and 39-0. The voting pattern suggests the measure was viewed as a technical or clarifying update to compounding rules rather than a controversial policy change.
Contention
No substantive opposition is reflected in the available voting history or committee materials. The main policy issue embedded in the bill is the scope of the exception for distribution within health systems, which may matter to pharmacies, hospitals, and regulators because it distinguishes internal hospital-system use from prohibited redistribution to outside entities. Secondary points of concern are the continued restrictions on compounding essentially copies of commercially available drugs, the emergency-use exceptions, and the special rules for veterinary compounding, but none of these appear to have generated recorded controversy.
A BILL to amend and reenact §§ 54.1-3406 and 54.1-3410.2 of the Code of Virginia, relating to Board of Pharmacy; compounding pharmacies; use of bulk drug substances; recordkeeping.
Patient Access to Urgent-Use Pharmacy Compounding Act of 2023 This bill relaxes certain requirements for compounding drugs that are facing shortages. Drug compounding is the process of mixing or otherwise altering drugs to create a medication. Currently, the Food and Drug Administration (FDA) allows for drug compounding subject to certain requirements. Generally, a licensed pharmacist or physician not registered with the FDA may only compound drugs in limited quantities for prescriptions for a specific individual patient. On the other hand, an FDA-registered outsourcing facility may compound drugs in bulk for use in medical facilities but is subject to additional requirements. This bill allows a compounder not registered with the FDA to compound drugs in limited quantities for an urgent medical need not involving a specific patient if, among other requirements (1) the prescriber certifies that the prescriber is unable, despite reasonable attempts, to obtain certain related drugs with the same active ingredient and route of administration; (2) the compounded drug meets certain labeling requirements, including an indication that the compounded drug is provided only for urgent administration to a patient; and (3) the compounder requests and maintains certain records about patients receiving the compounded drug. Furthermore, a restriction against an unregistered compounder regularly compounding (or compounding inordinate amounts of) what is essentially a copy of a commercially available drug shall not apply if the drug is on a shortage list maintained by the FDA or the American Society of Hospital Pharmacists.
Authorizes a pharmacy technician or pharmacy intern to perform technology-assisted dispensing process validation for medications prepared for distribution by another pharmacy technician or intern within an institutional pharmacy.